MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.27
+0.71
+10.82%
Pre Market: 8.38 +1.11 +15.27% 09:18 06/29 EDT
OPEN
6.52
PREV CLOSE
6.56
HIGH
7.98
LOW
6.52
VOLUME
2.43K
TURNOVER
--
52 WEEK HIGH
31.36
52 WEEK LOW
4.930
MARKET CAP
303.60M
P/E (TTM)
-5.2457
1D
5D
1M
3M
1Y
5Y
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 05/24 12:55
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter ended March 31, 2...
PR Newswire · 05/05 20:05
BRIEF-Tyra Biosciences Posts Q4 Net Loss Of $9.9 Million
reuters.com · 03/03 21:39
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter and year ended De...
PR Newswire · 03/03 21:05
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will be participating in a co...
PR Newswire · 02/22 21:05
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Cor...
GuruFocus.com · 12/21/2021 23:38
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 12/15/2021 14:29
Beware of These 3 Recent IPOs That are Overvalued
StockNews.com · 11/11/2021 15:56
More
No Data
Learn about the latest financial forecast of TYRA. Analyze the recent business situations of Tyra Biosciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TYRA stock price target is 21.67 with a high estimate of 27.00 and a low estimate of 12.00.
High27.00
Average21.67
Low12.00
Current 7.31
EPS
Actual
Estimate
-0.58-0.43-0.29-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 45
Institutional Holdings: 36.13M
% Owned: 86.52%
Shares Outstanding: 41.76M
TypeInstitutionsShares
Increased
12
2.13M
New
6
1.46M
Decreased
19
1.24M
Sold Out
6
1.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
+0.64%
Key Executives
Chief Financial Officer
Esther Van Den Boom
General Counsel
John Healy
Executive Officer/Primary Contact
Dan Bensen
Executive Officer
Todd Harris
Executive Officer
Robert Hudkins
Executive Officer
Ronald Swanson
Director
Rehan Verjee
No Data
No Data
About TYRA
Tyra Biosciences, Inc. is a precision oncology company. The Company is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The Company uses its proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The Company is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.

Webull offers kinds of Tyra Biosciences Inc stock information, including NASDAQ:TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.